Resmetirom Achieves Dual Histologic Endpoints in NASH Fibrosis

MAESTRO-NASH provides the first Phase 3 histologic evidence supporting an oral thyroid hormone receptor-beta agonist as pharmacotherapy for biopsy-confirmed nonalcoholic steatohepatitis with fibrosis, a condition previously without any approved drug.

📅 Journal publication: Feb 8, 2024 · Last updated: Oct 6, 2026

resmetiromRezdiffrathyroid hormone receptor-beta agonistNASHMASHnonalcoholic steatohepatitisliver fibrosishepatologyPhase 3 RCTLDL cholesterolMAESTRO-NASH Gastroenterology / Hepatology

Background Information

Resmetirom could be a breakthrough treatment for NASH with liver fibrosis.

Nonalcoholic steatohepatitis (NASH) is a serious liver condition with no approved treatments, highlighting the need for effective therapies. Resmetirom significantly improved NASH resolution and liver fibrosis in 25.9% to 29.9% of patients compared to 9.7% with placebo. This study indicates resmetirom may be a promising treatment for NASH, warranting further investigation in the clinical setting. Resmetirom shows promise in resolving NASH and improving liver fibrosis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V, MAESTRO-NASH Investigators

Citation: Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England journal of medicine. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →